---
title: "GH Research to Attend APA Annual Meeting in San Francisco in May 2026"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286252324.md"
description: "GH Research PLC announced its participation in the American Psychiatric Association Annual Meeting in San Francisco from May 16-20, 2026. This engagement highlights the company's commitment to psychiatric care and aims to enhance its visibility in the mental health treatment sector. Currently, GH Research has a Buy rating with a $70 price target, although it faces challenges such as no revenue and widening losses. The company focuses on developing treatments for mental health disorders and has a market cap of $1.48 billion."
datetime: "2026-05-13T11:30:51.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286252324.md)
  - [en](https://longbridge.com/en/news/286252324.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286252324.md)
---

# GH Research to Attend APA Annual Meeting in San Francisco in May 2026

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

GH Research ( (GHRS) ) has provided an announcement.

GH Research PLC announced on May 13, 2026, that it will attend the American Psychiatric Association Annual Meeting in San Francisco, California. The conference is scheduled to take place from May 16 to May 20, 2026, and the company’s participation underscores its engagement with leading clinicians and researchers in psychiatric care, potentially supporting its visibility and relationships within the mental health treatment landscape.

The most recent analyst rating on (GHRS) stock is a Buy with a $70.00 price target. To see the full list of analyst forecasts on GH Research stock, see the GHRS Stock Forecast page.

**Spark’s Take on GHRS Stock**

According to Spark, TipRanks’ AI Analyst, GHRS is a Neutral.

The score is held back primarily by weak financial performance (no revenue, widening losses, and ongoing cash burn), partly offset by a strong, low-leverage balance sheet. Technicals are supportive with clear upward trend and positive momentum, while valuation remains a drag due to negative earnings and no dividend.

To see Spark’s full report on GHRS stock, click here.

**More about GH Research**

GH Research PLC is an Ireland-based biopharmaceutical company focused on developing treatments in the field of psychiatry. The company targets mental health disorders, positioning itself within the broader neuropsychiatric therapeutics market and engaging closely with the psychiatric clinical and research community.

**Average Trading Volume:** 218,174

**Technical Sentiment Signal:** Buy

**Current Market Cap:** $1.48B

### Related Stocks

- [GHRS.US](https://longbridge.com/en/quote/GHRS.US.md)

## Related News & Research

- [These Analysts Revise Their Forecasts On GH Research After Q1 Results](https://longbridge.com/en/news/286585655.md)
- [GRI Bio to Present at A.G.P.’s Annual Healthcare Company Showcase | GRI Stock News](https://longbridge.com/en/news/286777671.md)
- [Akari Therapeutics to Present at A.G.P.’s Annual Healthcare Company Showcase | AKTX Stock News](https://longbridge.com/en/news/286776452.md)
- [ZAWYA: Ajmal Perfumes marks 75 years of excellence at TFWA Asia Pacific 2026](https://longbridge.com/en/news/287033450.md)
- [Ireland's GH Research Q1 net loss widens on higher expenses](https://longbridge.com/en/news/286406432.md)